Across TCGA pan-cancer cohorts, SMIM10 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SMIM10 data layer compared with 22 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher SMIM10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SMIM10 expression acts as an unfavorable survival marker.
ESCA are the cancer types where SMIM10 Mutation most reproducibly stratifies survival.